A new spin-off: ChromaCure
Cédric Blanpain, Director of the Stem Cell and Cancer Laboratory (Faculty of Medicine, U-CRC) has just created his spin-off, ChromaCure. Based at the Gosselies Biopark, the spin-off targets the regulators of tumor initiation and progression, discovered by the Stem Cell and Cancer Laboratory.
ChromaCure will develop a program to identify drug candidates that can inhibit these targets and launch first clinical trials. Led by Jalal Vakili, from the pharmaceutical group Servier, the spin-off has raised € 17 million from various investors.